Enrolling By Invitation PHASE3 INTERVENTIONAL 1-arm NCT07073014

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia (CANOPY-HCH-EXT)

A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia

Sponsor: BioMarin Pharmaceutical

Conditions Hypochondroplasia

Interventions Vosoritide

Updated 2 times since 2025 Last updated: Jul 9, 2025 Started: Jun 20, 2025 Primary completion: Dec 31, 2040 Completion: Dec 31, 2040

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypochondroplasia, this trial is ongoing. The trial is conducted by BioMarin Pharmaceutical and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Enrolling By Invitation PHASE3
Aug 2025 — Sep 2025 [monthly]

Enrolling By Invitation PHASE3

First recorded

Jun 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioMarin Pharmaceutical

Data source: BioMarin Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chicago, United States , Cologne, Germany , Edmonton, Canada , Genoa, Italy , London, United Kingdom , Lyon, France , Magdeburg, Germany , Marseille, France , Milwaukee, United States , Montreal, Canada and 12 more locations